Epstein-Barr Virus Infection and Immunoregulation

  • José Menezes
  • Jean Gosselin
  • Smriti Kundu
Chapter
Part of the Experimental Biology and Medicine book series (EBAM, volume 20)

Abstracts

The Epstein-Barr virus (EBV) is a well-known example of a human virus which interacts most intimately with the immune system. EBV is a polyclonal B lymphocyte activator, can immortalize B cells and, depending on situations, can also induce different T cell and cytokine activities (1–6). The present paper examines briefly several immunoregulatory aspects of EBV interaction with the immune system, many of which are pertinent to our understanding of immune controls over EBV infections. Various effects of EBV infection on cells of the immune system and their products are thus examined.

Keywords

Arthritis Depression Lymphoma Interferon Prostaglandin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. Rosen et al. Nature 267, 52 (1977).PubMedCrossRefGoogle Scholar
  2. 2.
    P.J. Sheldon et al. Lancet 1, 1153 (1973).PubMedCrossRefGoogle Scholar
  3. 3.
    P.K. Pattengale et al. J. Nat. Cancer Inst. 52, 1081 (1974).PubMedGoogle Scholar
  4. 4.
    J. Menezes et al. Infection and Immunity 13, 303 (1975).Google Scholar
  5. 5.
    J. Menezes et al. In “Viral Mechanisms of Immuno-suppression”, Progr. Leukocyte Biology 1, 115 (1985.).Google Scholar
  6. 6.
    G. Tosato, Adv. Cancer Res. 49, 75 (1987).PubMedCrossRefGoogle Scholar
  7. 7.
    W. Henle et al. Science 157, 1064 (1967).PubMedCrossRefGoogle Scholar
  8. 8.
    J.H. Pope et al. Int. J. Cancer 3, 867 (1968).CrossRefGoogle Scholar
  9. 9.
    A.C. Bird and S. Britton. Immunol. Rev. 45, 41 (1979).PubMedCrossRefGoogle Scholar
  10. 10.
    H. Kubagawa et al. In “Current Topics in Microbiology and Immunology”, Springer-Verlag, Berlin, 132, 246 (1986).Google Scholar
  11. 11.
    G. Henle and W. Henle. In “The Epstein-Barr virus” (M.A. Epstein, B.G. Achong, Eds.), Sping-Verlag, Berlin, 297 (1979).Google Scholar
  12. 12.
    P.K. Lai et al. Nature 252, 608 (1974).PubMedCrossRefGoogle Scholar
  13. 13.
    W.H. Wainwright et al. J. Infect. Dis. 140, 22 (1979).PubMedCrossRefGoogle Scholar
  14. 14.
    R.W. Veltri et al. J. Immunol 127, 320 (1981).PubMedGoogle Scholar
  15. 15.
    S.K. Sundar et al. Int. J. Immunopharmacol. 9, 869 (1987).PubMedCrossRefGoogle Scholar
  16. 16.
    S.K. Sundar and J. Menezes. Int. J. Immunopharmacol. 8, 101 (1986).PubMedCrossRefGoogle Scholar
  17. 17.
    S. Fong et al. J. Immunol. 126, 910 (1981).PubMedGoogle Scholar
  18. 18.
    C. Garzelli et al. J. Virol. 52, 722 (1984).PubMedGoogle Scholar
  19. 19.
    G.P. Allaway et al. J. Infect. Dis. 157 (5), 968 (1988).PubMedCrossRefGoogle Scholar
  20. 20.
    V.D. Mottironi and P.I. Terasaki. In “Histocompatibility Testing” (P.I. Terasaki. Ed.), Copenhegan, Munskeard, pp. 301–307 (1970).Google Scholar
  21. 21.
    P. Andersson, Acta. Pathol. Microbiol. Immunol. Scand, 83, 19 (1975)Google Scholar
  22. 22.
    B.A. Blazar et al. Cancer Res. 43, 4562 (1983).PubMedGoogle Scholar
  23. 23.
    J. Gordon et al. Nature 310, 145 (1984).PubMedCrossRefGoogle Scholar
  24. 24.
    G. Scala et al. J. Exp. Med. 159, 1637 (1984).PubMedCrossRefGoogle Scholar
  25. 25.
    B.A. Blazar et al. Cancer Immunol. Immunother. 22, 62 (1986).PubMedCrossRefGoogle Scholar
  26. 26.
    H. Wakasugi et al. Proc. Natl. Acad. Sci. USA 84, 804 (1987).PubMedCrossRefGoogle Scholar
  27. 27.
    S.K. Sundar et al. Clin. Exp. Immunol. 56, 701 (1984).PubMedGoogle Scholar
  28. 28.
    M. Lotz et al. J. Immunol. 136, 3643 (1986).PubMedGoogle Scholar
  29. 29.
    M. Jondal and G. Klein. J. Exp. Med. 138, 1365 (1973).PubMedCrossRefGoogle Scholar
  30. 30.
    G. Sauvageau et al. In “Epstein-Barr Virus and Human Disease”, (P.H. Levine, D.V. Ablashi et al. Eds.), Humana Press, Clifton, N.J., pp. 389–392 (1987).Google Scholar
  31. 31.
    E.L. Reinhertz et al. J. Immunol. 125, 1269 (1980).Google Scholar
  32. 32.
    B.F. Haynes et al. J. Immunol. 123, 2095 (1979).PubMedGoogle Scholar
  33. 33.
    H.E. Johnsen et al. Scand. J. Immunol. 10, 251 (1979).PubMedCrossRefGoogle Scholar
  34. 34.
    G. Tosato et al. N. Eng. J. Med. 301, 1133 (1979).CrossRefGoogle Scholar
  35. 35.
    S.K. Sundar and J. Menezes. Int. J. Cancer 35, 351 (1985).PubMedCrossRefGoogle Scholar
  36. 36.
    S.K. Sundar and J. Menezes. Microbial. Pathogenesis, 2, 259 (1987).PubMedCrossRefGoogle Scholar
  37. 37.
    T. Tursz et al. Nature 269, 806 (1977).PubMedCrossRefGoogle Scholar
  38. 38.
    M. Lipinski et al. J. Exp. Med. 150, 1310 (1979).PubMedCrossRefGoogle Scholar
  39. 39.
    E. Klein et al. In “Cold Spring Harbor Conf. Cell Prolif. 7, 1187 (1980).Google Scholar
  40. 40.
    P.C. Patel et al. Infection and Immunity 38, 251 (1982).PubMedGoogle Scholar
  41. 41.
    A. Ducantenzeiler and J. Menezes. Int. J. Immunopharmacol. 10, 81 (1988).CrossRefGoogle Scholar
  42. 42.
    S.K. Sundar et al. Int. J. Cancer 29, 407 (1982).PubMedCrossRefGoogle Scholar
  43. 43.
    F.K. Mathew et al. J. Cancer 27, 175 (1981).Google Scholar
  44. 44.
    E. Svedmyr et al. Clin. Immunol. Immunopathol. 30, 437 (1984).PubMedCrossRefGoogle Scholar
  45. 45.
    E. Svedmyr and M. Jondal. Proc. Nat. Acad. Sci. 72, 1622 (1975).PubMedCrossRefGoogle Scholar
  46. 46.
    I.S. Misko et al. Proc. Nat. Acad. Sci. 77, 4729 (1980).CrossRefGoogle Scholar
  47. 47.
    A. B. Rickinson et al. Nature 283, 865 (1980).PubMedCrossRefGoogle Scholar
  48. 48.
    D. J. Moss et al. Eur. J. Immunol. 11, 686 (1981).PubMedCrossRefGoogle Scholar
  49. 49.
    L. E. Wallace et al. Eur. J. Immunol. 12, 1012 (1982)PubMedCrossRefGoogle Scholar
  50. 50.
    S.C. Meurer et al. J. Immunol, 131, 186 (1983).Google Scholar
  51. 51.
    I.S. Misko et al. Int. J. Cancer, 33 239 (1984).PubMedCrossRefGoogle Scholar
  52. 52.
    I. S. Misko et al. In “Epstein-Barr Virus and Human Disease”, (P.H. Levine, D.V. Ablashi et al. Eds), Humana Press, Clifton, New Jersey, pp. 343–347 (1987).Google Scholar
  53. 53.
    B.M. Carreno et al. J. Exp. Clinical Cancer Res. 7, 99 (1988 - Supplement).Google Scholar
  54. 54.
    M. Lotz et al. Eur. J. Immunol. 15, 120 (1985).CrossRefGoogle Scholar
  55. 55.
    D.A. Thorley-Lawson. J. Immunol. 126, 829 (1981).PubMedGoogle Scholar
  56. 56.
    M. Andersson et al. Eur. J. Immunol. 13, 6 (1983).PubMedCrossRefGoogle Scholar
  57. 57.
    F. Hasler et al. J. Exp. Med. 157, 173 (1983).PubMedCrossRefGoogle Scholar
  58. 58.
    T. C. Shope and J. Kaplan. J. Immunol. 123, 2150 (1979).PubMedGoogle Scholar
  59. 59.
    P.A. Bardwich et al. Arthritis Reum. 23, 626 (1980).CrossRefGoogle Scholar
  60. 60.
    M.G. Masucci et al. Cell. Immunol. 76, 311 (1983).PubMedCrossRefGoogle Scholar
  61. 61.
    F. Wang et al. Clin. Res. 33, 391 (1985).Google Scholar
  62. 62.
    J. Menezes et al. Nature, 260, 430 (1976).PubMedCrossRefGoogle Scholar
  63. 63.
    S. Kohl et al. J. Pediatr. 112, 976 (1988).PubMedCrossRefGoogle Scholar
  64. 64.
    J. Gosselin et al. (submitted for publication)Google Scholar

Copyright information

© The Humana Press Inc. 1989

Authors and Affiliations

  • José Menezes
    • 1
  • Jean Gosselin
    • 1
  • Smriti Kundu
    • 1
  1. 1.Laboratory of Immunovirology, Pediatric Research CenterSte-Justine Hospital & University of MontrealMontrealCanada

Personalised recommendations